CLINICAL TRIALS PROFILE FOR SOLIFENACIN SUCCINATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for SOLIFENACIN SUCCINATE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT01565707 ↗ | A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug | Completed | Astellas Pharma Europe B.V. | Phase 3 | 2012-06-07 | Solifenacin succinate as a tablet formulation is already on the market for the treatment of symptoms of overactive bladder in adults. For the use in children and adolescent patients a new formulation of solifenacin has been developed. This study investigated the effect and safety of solifenacin succinate liquid suspension compared to a non-active drug (placebo) over a 12-week period. The 2 weeks prior to the double blind period was a single-blind placebo run-in period in combination with behavioral urotherapy (Non-interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB), followed by a 12 week daily treatment period. The study also investigated how well solifenacin succinate suspension is taken-up by the body and how long it stays in the body during this time. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for SOLIFENACIN SUCCINATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00189800 ↗ | A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder | Completed | Astellas Pharma Korea, Inc. | Phase 3 | 1969-12-31 | The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder. |
| NCT00189800 ↗ | A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 1969-12-31 | The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder. |
| NCT00333112 ↗ | A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. | Completed | Astellas Pharma Inc | Phase 4 | 2006-05-01 | A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men. |
| NCT00337558 ↗ | A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) | Completed | Astellas Pharma Europe B.V. | Phase 4 | 2006-05-01 | This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes. |
| NCT00337558 ↗ | A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) | Completed | Astellas Pharma Inc | Phase 4 | 2006-05-01 | This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes. |
| NCT00368706 ↗ | A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients | Completed | Astellas Pharma Inc | Phase 3 | 2006-09-01 | To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid |
| NCT00454740 ↗ | Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2004-06-01 | To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SOLIFENACIN SUCCINATE
Condition Name
Clinical Trial Locations for SOLIFENACIN SUCCINATE
Trials by Country
Clinical Trial Progress for SOLIFENACIN SUCCINATE
Clinical Trial Phase
Clinical Trial Sponsors for SOLIFENACIN SUCCINATE
Sponsor Name
